New hemophilia drug aims to outperform standard therapy in major trial
NCT ID NCT07416526
Summary
This study aims to see if a new preventive treatment called NXT007 works better and is as safe as the current standard factor VIII injections for people with moderate or severe hemophilia A. It will involve about 126 people aged 12 and older who are already using factor VIII to prevent bleeds. Researchers will compare how often participants have bleeds that need treatment and measure the impact on daily life.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMOPHILIA A are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.